Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Announces the Launch of Colchicine Tablets USP, 0.6 mg in the U.S. Market

Retrieved on: 
Friday, June 12, 2020
Biotechnology, FDA, Pharmaceutical, Health, Articles, Organic compounds, Drugs, RTT, Acetamides, Alkaloids, Colchicine, Dr. Reddy's Laboratories, Generic drug, IQVIA

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Colchicine Tablets USP, a therapeutic equivalent generic version of Colcrys (colchicine) Tablets, 0.6 mg, approved by the U.S. Food and Drug Administration (USFDA).

Key Points: 
  • Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Colchicine Tablets USP, a therapeutic equivalent generic version of Colcrys (colchicine) Tablets, 0.6 mg, approved by the U.S. Food and Drug Administration (USFDA).
  • The Colcrys brand and generic market had U.S. sales of approximately $491 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health*.
  • Dr. Reddys Colchicine is available in 0.6 mg tablets in bottle count sizes of 30s and 100s.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.

Dr. Reddy’s Laboratories Completes the Acquisition of Select Business Divisions of Wockhardt

Retrieved on: 
Wednesday, June 10, 2020
Biotechnology, General Health, Health, Pharmaceutical, Clinical trials, CNX Nifty, Dr. Reddy's Laboratories, Companies, Wockhardt, Economy of India

Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's") (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announces that it has completed the acquisition of select divisions of Wockhardt Limiteds (Wockhardt) branded generics business in India and a few other international territories of Nepal, Sri Lanka, Bhutan and Maldives.

Key Points: 
  • Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's") (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announces that it has completed the acquisition of select divisions of Wockhardt Limiteds (Wockhardt) branded generics business in India and a few other international territories of Nepal, Sri Lanka, Bhutan and Maldives.
  • On February 12, 2020, Dr. Reddys signed a Business Transfer Agreement (BTA) with Wockhardt, to acquire the above-referred business undertaking for an upfront consideration of Rs.1,850 Crores.
  • Subsequently, through an amendment to the BTA, Dr. Reddys and Wockhardt have agreed that the deal consideration shall now be upto Rs.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.

Global Pharmaceutical Contract Manufacturing Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025

Retrieved on: 
Thursday, June 4, 2020
Health, Pharmaceutical industry, Articles, Pharmacology, Pharmacy, Pharmaceutical manufacturing, Manufacturing, Contract manufacturer, Pharmaceutical industry in China, Dr. Reddy's Laboratories

On the basis of Type of Contract Manufacturing, the Global Pharmaceutical Contract Manufacturing Market is studied across API or Bulk Drug Manufacturing and Final Dosage Form.

Key Points: 
  • On the basis of Type of Contract Manufacturing, the Global Pharmaceutical Contract Manufacturing Market is studied across API or Bulk Drug Manufacturing and Final Dosage Form.
  • What are the factors that affect the growth in the Global Pharmaceutical Contract Manufacturing Market over the forecast period?
  • Which are the best product areas to be invested in over the forecast period in the Global Pharmaceutical Contract Manufacturing Market?
  • What are the modes of entering the Global Pharmaceutical Contract Manufacturing Market?

UPS Healthcare Provides Urgent Support For Dr. Reddy’s Laboratories’ Temperature-Sensitive Medicines

Retrieved on: 
Monday, May 18, 2020
Articles, Health, CNX Nifty, Dr. Reddy's Laboratories, Coronavirus, Essential medicines, Pandemic, Medicine

Given the supply chain challenges and restrictions due to the Coronavirus pandemic, UPS Healthcare and Dr. Reddys created an emergency supply chain plan to replenish pharmaceutical stocks in U.S. markets.

Key Points: 
  • Given the supply chain challenges and restrictions due to the Coronavirus pandemic, UPS Healthcare and Dr. Reddys created an emergency supply chain plan to replenish pharmaceutical stocks in U.S. markets.
  • During this pandemic, moving critical controlled room temperature medicines requires extra planning given the air market capacity demand levels, said Wes Wheeler, president of UPS Healthcare.
  • Dr. Reddys Laboratories aims to ensure that essential medicines are within reach of patients by maintaining an uninterrupted supply globally.
  • UPS Healthcare provides global supply chain solutions and expertise to pharmaceutical, biopharma and medical device companies.

Dr. Reddy's to release Q4 and full year FY 20 results on May 20, 2020

Retrieved on: 
Thursday, May 7, 2020
General Health, Pharmaceutical, Health, Life sciences, CNX Nifty, Articles, Dr. Reddy's Laboratories, Biotechnology, Industries, Biosimilar, Lupin Limited

The operator will provide instructions on asking questions before and during the call.

Key Points: 
  • The operator will provide instructions on asking questions before and during the call.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products Dr. Reddys offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.
  • Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

Dr. Reddy's Laboratories Announces the Launch of Desmopressin Acetate Injection USP, 4 mcg/mL in the U.S. Market

Retrieved on: 
Wednesday, May 6, 2020
Biotechnology, FDA, Pharmaceutical, Health, RTT, Drugs, Desmopressin, Peptides, Dr. Reddy's Laboratories, Companies, Dr. Reddy’s, SunGen Pharma LLC:

The DDAVP (desmopressin acetate) Injection USP brand and generic market had U.S. sales of approximately $20.9 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health*.

Key Points: 
  • The DDAVP (desmopressin acetate) Injection USP brand and generic market had U.S. sales of approximately $20.9 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health*.
  • Marc Kikuchi, CEO, North America Generics, Dr. Reddys Laboratories, commented, The launch of Desmopressin Injection demonstrates a strong, growing collaboration with SunGen Pharma.
  • Isaac Liu, Ph.D., Co-CEO of SunGen, stated, "We are pleased to be working with Dr. Reddys for this launch.
  • Dr. Reddys Desmopressin Acetate Injection USP, 4 mcg/mL is available in a carton of ten 1 mL single-dose ampules.

Dr. Reddy's Laboratories Announces the Launch of Fenofibrate Tablets USP, in the U.S. Market

Retrieved on: 
Monday, April 27, 2020
Biotechnology, FDA, Pharmaceutical, Health, Articles, Chemistry, RTT, Life sciences, Chloroarenes, Benzophenones, Fenofibrate, Prodrugs, CNX Nifty, Dr. Reddy's Laboratories, Generic drug, IQVIA

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Fenofibrate Tablets USP, a therapeutic equivalent generic version of Tricor (fenofibrate) Tablets, approved by the U.S. Food and Drug Administration (USFDA).

Key Points: 
  • Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Fenofibrate Tablets USP, a therapeutic equivalent generic version of Tricor (fenofibrate) Tablets, approved by the U.S. Food and Drug Administration (USFDA).
  • The Tricor brand and generic had U.S. sales of approximately $90 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health*.
  • Dr. Reddys Fenofibrate Tablets USP, are available in 54 mg dose in bottle count size of 90 and 160 mg dose in bottle count sizes of 90 and 500.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.

Dr. Reddy's Laboratories Announces the Launch of an Authorized Generic Version of NitroDur® (nitroglycerin) Transdermal Infusion System in the U.S. Market

Retrieved on: 
Tuesday, April 14, 2020
Health, Pharmaceutical, Health, Pharmacology, Articles, Routes of administration, RTT, CNX Nifty, Dr. Reddy's Laboratories, Transdermal patch, Reddy, Nitroglycerin, IQVIA, Generic drug

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of authorized generic version of NitroDur (nitroglycerin) Transdermal Infusion System.

Key Points: 
  • Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of authorized generic version of NitroDur (nitroglycerin) Transdermal Infusion System.
  • The combined market for all Nitrogylcerin Transdermal Patch products had U.S. sales of approximately $14.7 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health*.
  • Dr. Reddys Nitroglycerin Transdermal Infusion System is available in four dosage strengths: 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, and 0.6 mg/hr, each in a box of 30 count.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.

Dr. Reddy's Laboratories announces the launch of Amphetamine Sulfate Tablets USP, in the U.S. Market

Retrieved on: 
Tuesday, April 14, 2020
General Health, Health, Science, Pharmaceutical, Research, Psychoactive drugs, Drugs, Substituted amphetamines, Stimulants, Ergogenic aids, Euphoriants, Phenethylamines, Amphetamine, Dr. Reddy's Laboratories, Generic drug

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Amphetamine Sulfate Tablets USP, a therapeutic equivalent generic version of Evekeo (amphetamine sulfate) Tablets approved by the U.S. Food and Drug Administration (USFDA).

Key Points: 
  • Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Amphetamine Sulfate Tablets USP, a therapeutic equivalent generic version of Evekeo (amphetamine sulfate) Tablets approved by the U.S. Food and Drug Administration (USFDA).
  • Amphetamine Sulfate Tablets, USP is a Schedule II drug.
  • The Evekeo brand and generic had U.S. sales of approximately $38 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health*.
  • Dr. Reddys Amphetamine Sulfate Tablets USP are available in 5 mg and 10 mg dose in bottle count sizes of 100.

Global Active Pharmaceutical Ingredients Market 2020-2024 | Evolving Opportunities with Amneal Pharmaceuticals Inc. and Cadila Healthcare Ltd. | Technavio

Retrieved on: 
Friday, April 10, 2020
Research, Chemicals, Plastics, Marketing, Communications, Manufacturing, Biotechnology, Health, Pharmaceutical, Science, Health, Articles, Pharmaceuticals policy, Amneal Pharmaceuticals, Pharmaceutical industry in China, Pharmaceutical industry in India, Pharmaceutical industry, Teva Pharmaceutical Industries, Dr. Reddy's Laboratories

In addition, the paradigm shift in API manufacturing is anticipated to boost the growth of the active pharmaceutical ingredients market.

Key Points: 
  • In addition, the paradigm shift in API manufacturing is anticipated to boost the growth of the active pharmaceutical ingredients market.
  • These factors are fueling the growth of the global active pharmaceutical ingredients market.
  • Major Five Active Pharmaceutical Ingredients Companies:
    Amneal Pharmaceuticals Inc. operates the business across segments such as Generics and Specialty.
  • Active Pharmaceutical Ingredients Market Type Outlook (Revenue, USD Billion, 2020-2024)
    Active Pharmaceutical Ingredients Market Geographic Landscape Outlook (Revenue, USD Billion, 2020-2024)